Last updated: July 4, 2026
ecutive summary: No complete litigation summary can be produced from the case identifier alone. A litigation analysis requires the docket record (claims asserted, asserted patents, parties, procedural posture, schedules, and outcomes) and/or the operative complaint and any district-court orders. Without those filings and events, a patent-litigation narrative and exclusivity or launch-risk analysis for Imprimis Pharmaceuticals, Inc. v. Alcon Pharmaceuticals Ltd. (3:16-cv-01794) cannot be stated accurately.
Litigation summary: What happened in Imprimis Pharmaceuticals, Inc. v. Alcon Pharmaceuticals Ltd. (3:16-cv-01794)?
No complete summary is available from the case caption and docket number alone. A litigation summary must reference the asserted IP (patent numbers), the specific theories (infringement, inducement, willful infringement), the relief sought (injunction, damages, declaratory judgment), and the adjudicated orders (motions, claim construction if applicable, settlement or judgment dates). Those particulars are not present in the provided information.
What patents were asserted by Imprimis against Alcon in 3:16-cv-01794?
A patent-by-patent identification is required to analyze infringement scope, venue-specific rulings, and expiration or exclusivity impact. That asserted-patent list is not available in the provided prompt.
Which Imprimis assets (formulations, devices, methods) were at issue?
Patent-level detail is necessary to map the allegation to:
- drug product formulation IP (composition, preservative systems, viscosity/penetration aids),
- method-of-use IP (indications, dosing regimens),
- manufacturing/processing IP (sterility, mixing steps, container/closure handling),
- or device delivery IP (if the allegation covered administration).
Which Alcon product(s) and dosage forms were accused?
A correct infringement analysis depends on the accused product, strength, regimen, and route. Those details are not available.
What was the procedural posture in Imprimis v. Alcon (3:16-cv-01794): complaint, motions, and outcomes?
A true procedural timeline requires docket events (filing dates, motion dates, hearing outcomes, order dates, and final disposition). None are provided.
Was there a claim construction phase?
If the case involved patent litigation, claim construction orders often drive the infringement analysis. That is not available.
Were there summary-judgment rulings, trial, or consent judgment?
Disposition type determines business impact (injunction likelihood, damages exposure, appeal risk). That information is not available.
Did the case end in settlement?
Settlement status is essential for assessing generic or branded launch timing, licensing terms, and enforcement posture. Settlement terms require docket/filing record.
How strong was Imprimis’s patent estate in 3:16-cv-01794?
A strength analysis requires:
- asserted claims and their independent/dependent structure,
- validity posture (prior art, obviousness, enablement),
- infringement evidence quality (samples, ANDA/BLA labels, sales data, manufacturing records),
- claim construction outcomes,
- and any court findings.
Those inputs are not present.
Did Alcon assert invalidity or noninfringement defenses in 3:16-cv-01794?
A defense mapping depends on what Alcon argued in motions to dismiss/for summary judgment and in claim-construction positions. No defense record is provided.
What Paragraph IV or FDA exclusivity issues were implicated (if any)?
If the dispute was tied to an FDA approval or a generic/biosimilar pathway, the analysis must identify:
- the FDA application type (ANDA, NDA, BLA),
- Orange Book listings and patent numbers,
- the statutory basis (Hatch-Waxman 30/180-day exclusivity, 21 USC 355(j) litigation),
- and any FDA letters or exclusivity determinations.
No FDA pathway details are included.
What is the Orange Book status of the patents at issue in 3:16-cv-01794?
Orange Book status requires the specific patents and NDA reference number(s). Without the asserted-patent list and the NDA/Reference Listed Drug, an Orange Book table cannot be constructed.
What generic entry risks existed for Alcon or Imprimis under 3:16-cv-01794?
Risk requires identifying whether the litigation was an ANDA 355(j) suit, what the court decided, and what the exclusivity/patent expiration dates are. None of that is available.
How does Imprimis’s litigation position in 3:16-cv-01794 compare with other Imprimis patent cases?
A credible comparison requires at least:
- the drug product and patent family,
- the same or different delivery/indication,
- and a known set of prior rulings or settlement patterns.
The necessary case facts are missing.
Key Takeaways
- A complete litigation summary and patent-specific analysis for Imprimis Pharmaceuticals, Inc. v. Alcon Pharmaceuticals Ltd. (3:16-cv-01794) cannot be produced from the case number alone.
- Patent-litigation impact depends on asserted patent numbers, product mapping, docket events, and final disposition, none of which are provided.
FAQs
- What did the court decide in Imprimis v. Alcon (3:16-cv-01794)?
- Which patents were asserted by Imprimis in case 3:16-cv-01794?
- Did Imprimis win an injunction or damages in 3:16-cv-01794?
- Was 3:16-cv-01794 tied to an ANDA Paragraph IV certification or FDA exclusivity?
- Did the parties settle, and did that affect launch timing?
References
(No sources were cited because no docket, complaint, or order information was provided in the prompt.)
